http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-077974-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28e3113097dd6d28720572e47f2f2407 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| filingDate | 2010-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-077974-A1 |
| titleOfInvention | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS MOTOR INHIBITORS |
| abstract | Pharmaceutical compositions, kits and manufactured articles comprising such compounds are also provided; methods of use of the compounds. Claim 1: A compound of the formula (1) G1 is selected from the group consisting of N and CR7; G2 is selected from the group consisting of C = O and CH2; Ar is selected from the group consisting of C4-14 aryl and C1-10 heteroaryl; m is 0, 1, 2, 3 or 4; R1 is independently selected, taken each time, from the group consisting of halo, cyano, optionally substituted C1-6 alkyl, C1-8 sulfonyl, optionally substituted C2-4 alkenyl, optionally substituted C2-4 alkynyl, C1-4 alkoxy optionally substituted, C0-8-amino alkyl, optionally substituted C4-14 aryl, optionally substituted C4-14-oxy aryl, optionally substituted C1-10-oxy heteroaryl, C1-5 oxycarbonyl, C1-5 carbonyloxy, optionally C3-8 cycloalkyl substituted, optionally substituted C3-6 heterocycloalkyl, optionally substituted C1-10 heteroaryl, hydroxy, nitro, -C (O) NR8R9, -NHC (O) NR8R9, - NHC (O) OR10, -NH (SO2) NHR8, -NHC (O) NHNR8R9, -NHC (S) NR8R9, -NHC (= NR11) NR8R9, -NHC (SR12) NR8R9 and -NHC (NR11) OR13; R2 is selected from the group consisting of hydrogen, halo, cyano, optionally substituted C1-6 alkyl, C1-8 sulfonyl, optionally substituted C2-4 alkenyl, optionally substituted C2-4 alkynyl, optionally substituted C1-4 alkoxy, C0- alkyl 8-amino, optionally substituted C4-14 aryl, optionally substituted C4-14-oxy aryl, C1-5 oxycarbonyl, C1-5 carbonyloxy, optionally substituted C3-6 heterocycloalkyl, optionally substituted C1-10 heteroaryl, hydroxy and nitro; R3 is selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl and optionally substituted C3-6 heterocycloalkyl; R4 is selected from the group consisting of methyl and trifluoromethyl; R5 is selected from the group consisting of hydrogen, halo, optionally substituted C1-6 alkyl, optionally substituted C2-4 alkenyl and optionally substituted C3-8 cycloalkyl; R6 is selected from the group consisting of hydrogen, halo, optionally substituted C1-6 alkyl, optionally substituted C2-4 alkenyl and optionally substituted C38 cycloalkyl; or R5 and R6 are taken together to form an optionally substituted C1-3 alkylenyl; or R4 and R5 are taken together to form an optionally substituted C1-3 alkylenyl; or R4 and R6 are taken together to form an optionally substituted C1-3 alkylenyl; and R7 is selected from the group consisting of hydrogen, C0-8-amino alkyl, C1-7 amido, C1-9 amide, C1-5 carbamoyl, C1-6 sulfonylamide, C0-6 sulfonylamino, C1-5 ureido, C1 alkyl -4 optionally substituted, optionally substituted C1-4 alkoxy, cyano, halo, hydroxyl, nitro, C1-5 oxycarbonyl and C1-8 sulfonyl; R8 is independently selected, taken each time, from the group consisting of hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C4-14 aryl, optionally substituted C3-6 heterocycloalkyl and C1-10 heteroaryl optionally substituted; R9 is independently selected, taken each time, from the group consisting of hydrogen, optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C4-14 aryl, optionally substituted C3-6 heterocycloalkyl and C1-10 heteroaryl optionally substituted; R10 is independently selected, taken each time, from the group consisting of optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C4-14 aryl and optionally substituted C3-6 heterocycloalkyl; R11 is independently selected, taken each time, from the group consisting of hydrogen, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, optionally substituted C3-8 cycloalkyl, optionally substituted C4-14 aryl, C3-6 heterocycloalkyl optionally substituted, optionally substituted C1-10 heteroaryl, cyano and nitro; R12 is independently selected, taken each time, from the group consisting of optionally substituted C1-6 alkyl and optionally substituted phenyl; and R13 is independently selected, taken each time, from the group consisting of optionally substituted C1-6 alkyl, optionally substituted C3-8 cycloalkyl and optionally substituted C4-14 aryl; or its pharmaceutically acceptable salts. |
| priorityDate | 2009-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 26.